-
Syria site infrastructure 'consistent with nuclear reactor': IAEA
-
Man City set to sign Fernandez for record fee, Ndiaye on deadline day
-
Juventus sign Woltemade, Sarr on loan from Premier League
-
Back-to-school in Cuba a grim day with shortages of everything
-
US strikes Iran in latest tit-for-tat attacks
-
Canadian minister says Russia's G20 presence sparked 'discomfort'
-
China's Xi arrives in Egypt as US sanctions threat looms over Iran links
-
IMF reaches agreement with Senegal on new $2.2 bn loan programme
-
Car bomb at Colombian police station kills one, injures 11
-
Germany blames Russia for airport drone incident, hits back with sanctions
-
Rain delays start of play on US Open
-
Iran president urges return to truce, hails Russian support
-
Man City agree blockbuster deal to sign Chelsea star Fernandez: reports
-
Aster and World Liberty Financial Launch USD1 RWA Boost: Phase 1, Offering 125M $WLFI + 6.25M USD1 in Rewards
-
Alkemya Metacore Secures $50M via Tokenised Equity to Scale Nickel Energy and Security Tech
-
Tronchon sprints to Vuelta stage 10 win, Mas keeps red jersey
-
Man City chase Fernandez, Arsenal sell Jesus on deadline day
-
Germany defender Rudiger announces international retirement
-
EU says Russian 'hybrid attacks' won't halt aid to Ukraine
-
Musk defends AI data centers, slams EU rules at G20
-
Explosives used in sabotage attack on German power lines
-
Activists blame Kenya for Ugandan opposition figure's plight
-
Nepali families hold symbolic funerals for missing after floods
-
Iran president offers US olive branch, hails Russian support
-
Newcastle sign Lille forward Fernandez-Pardo
-
TrustFinance Community Choice Awards 2026 Opens Global Voting
-
Even at Elysee, phones are handed in, Macron tells French pupils
-
Nepal disaster a climate 'warning signal': foreign minister
-
Chelsea agree to sign Atalanta's Ahanor, with Palace loan for this season
-
France winger Diaby returns to Leverkusen until 2031
-
Chelsea sign Atalanta's Ahanor and loan him to Palace
-
Barcelona confirm Jesus arrival from Arsenal
-
UK chalks up hottest summer on record for second year running
-
EU official says it's not time to 'normalize' Russia at G20 finance talks
-
China's Xi visits Egypt as US sanctions threat looms over Iran links
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
-
RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology
-
TrendEadvisor Launches Global Multi-Asset Platform Combining Online Investing with Social Trading
-
Global bond sell-off deepens on inflation concerns
-
India's top court drops criminal cases against protesters
-
Germany's far-right AfD promises 'boom' but economists fear worst
-
Philippine couple married in hip-deep floodwaters
-
Former England captain Stokes signs for Adelaide Strikers
-
Villa sign Senegal winger Mbaye from PSG
-
Pakistan selector and ex-captain Misbah resigns after coach sacked
-
Former Peru minister last-minute contender for UN labour agency helm
-
Shein flattens on Hong Kong debut facing global headwinds
-
Messi legacy will 'live forever', says Beckham
-
Eurozone inflation hits three-year high at 3.3% in August
-
'Literally tasting the smoke': Malaysians suffer as haze worsens
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event:
Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET
A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website.
A replay of this webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
J.Gomez--AT